Balancing Efficacy and Safety With Finerenone in Patients With Heart Failure and Chronic Kidney Disease

Puntos clave

• The aim is to evaluate the efficacy and safety of finerenone in patients with heart failure and chronic kidney disease.
• Randomized trial design
• Assessment of efficacy and safety outcomes
• Inclusion of patients with heart failure and chronic kidney disease
• Finerenone significantly improved heart failure outcomes compared to standard treatment (p<0.05).
• Safety profile indicated a lower incidence of adverse events related to kidney function (HR 0.80, 95% CI 0.65-0.90, p=0.02).
• Improvement in biomarkers relevant to heart failure and kidney function was noted.